|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue: | |||||
| Revenue | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Research and development expense | |||||
| General and administrative expense | |||||
| Litigation legal expense | |||||
| Right-of-use asset impairment loss | |||||
| Loss from sale of property and equipment | |||||
| Gain on early lease termination | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other income (expense), net: | |||||
| Changes in fair value of investment in convertible notes receivable | |||||
| Dividend income | |||||
| Interest income | |||||
| Interest expense | |||||
| Gain on settlement of accounts payables | |||||
| Change in fair value of contingent liability | |||||
| Other income (expense), net | |||||
| Total other income (expense), net | |||||
| Net loss before provision for income taxes | |||||
| Provision (benefit) for income taxes | |||||
| Net loss | |||||
| Basic loss per common share (in USD per share) | |||||
| Diluted loss per common share (in USD per share) | |||||
| Weighted-average basic common shares outstanding (in shares) | |||||
| Weighted-average diluted common shares outstanding (in shares) |
Loading...